Steve Fuller

1.2k total citations
20 papers, 873 citations indexed

About

Steve Fuller is a scholar working on Molecular Biology, Epidemiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Steve Fuller has authored 20 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Epidemiology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Steve Fuller's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Pneumonia and Respiratory Infections (3 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Steve Fuller is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Pneumonia and Respiratory Infections (3 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Steve Fuller collaborates with scholars based in United States, Vietnam and Germany. Steve Fuller's co-authors include Ali Fattom, Gary Horwith, Robert Naso, Larry R. Muenz, Henry R. Shinefield, David Law, Rachel Schneerson, Juan Antonio Ordóñez Pereda, Harry Alcorn and Hock H. Yeoh and has published in prestigious journals such as New England Journal of Medicine, The Journal of Immunology and PLoS ONE.

In The Last Decade

Steve Fuller

19 papers receiving 839 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve Fuller United States 11 450 393 204 134 120 20 873
Gayathri Arakere India 20 487 1.1× 498 1.3× 217 1.1× 180 1.3× 54 0.5× 31 954
Jawad Sarwar United States 9 363 0.8× 278 0.7× 123 0.6× 172 1.3× 107 0.9× 15 596
A. M. J. J. Verweij-Van Vught Netherlands 15 174 0.4× 299 0.8× 119 0.6× 126 0.9× 129 1.1× 33 911
Minako Araake Japan 14 228 0.5× 249 0.6× 154 0.8× 92 0.7× 215 1.8× 48 818
M. Campa Italy 15 271 0.6× 148 0.4× 280 1.4× 113 0.8× 283 2.4× 61 801
Jean Kirihara United States 12 414 0.9× 285 0.7× 242 1.2× 21 0.2× 161 1.3× 12 1.1k
C Cellesi Italy 16 306 0.7× 118 0.3× 363 1.8× 98 0.7× 61 0.5× 57 746
Thomas E. Grys United States 19 449 1.0× 244 0.6× 344 1.7× 34 0.3× 65 0.5× 63 1.2k
Imad Kansau France 19 586 1.3× 329 0.8× 324 1.6× 53 0.4× 364 3.0× 30 1.4k
Ashley Keller United States 16 267 0.6× 542 1.4× 204 1.0× 172 1.3× 331 2.8× 29 1.4k

Countries citing papers authored by Steve Fuller

Since Specialization
Citations

This map shows the geographic impact of Steve Fuller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Fuller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Fuller more than expected).

Fields of papers citing papers by Steve Fuller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Fuller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Fuller. The network helps show where Steve Fuller may publish in the future.

Co-authorship network of co-authors of Steve Fuller

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Fuller. A scholar is included among the top collaborators of Steve Fuller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Fuller. Steve Fuller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raleigh, Michael D., Nicola Beltraminelli, Mark LeSage, et al.. (2021). Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies. PLoS ONE. 16(7). e0254247–e0254247. 5 indexed citations
2.
Nagaoka, Katsuya, Xuewei Bai, Kosuke Ogawa, et al.. (2019). Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. Cancer Letters. 449. 87–98. 19 indexed citations
3.
Nordquist, Luke T., Hossein Ghanbari, J C Oliver, et al.. (2018). Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer. Annals of Oncology. 29. viii136–viii136. 2 indexed citations
4.
Iwagami, Yoshifumi, Sarah Casulli, Katsuya Nagaoka, et al.. (2017). Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 3(9). e00407–e00407. 36 indexed citations
5.
Keyler, Daniel E., Samuel A. Roiko, Mark LeSage, et al.. (2005). MONOCLONAL NICOTINE-SPECIFIC ANTIBODIES REDUCE NICOTINE DISTRIBUTION TO BRAIN IN RATS: DOSE- AND AFFINITY-RESPONSE RELATIONSHIPS. Drug Metabolism and Disposition. 33(7). 1056–1061. 61 indexed citations
6.
Fattom, Ali, Steve Fuller, Scott Winston, et al.. (2004). Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX®) in hemodialysis patients. Vaccine. 23(5). 656–663. 75 indexed citations
7.
8.
Shinefield, Henry R., Steven Black, Ali Fattom, et al.. (2002). Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis. New England Journal of Medicine. 346(7). 491–496. 351 indexed citations
9.
Allsop, David, G.S. Christie, Sandra L. Holmes, et al.. (1997). Studies on inhibition of β-amyloid formation in APP-751-transfected IMR-32 cells, and SPA4CT-transfected SHSY5Y cells. Lancaster EPrints (Lancaster University). 2 indexed citations
10.
Allsop, David, G.S. Christie, Sandra L. Holmes, et al.. (1996). 588 Studies on inhibition of βA4 formation in APP-751 transfected IMR-32 cells, and SPA4CT transfected SHSYSY cells. Neurobiology of Aging. 17(4). S146–S146.
11.
Evin, Geneviève, Anna Henry, Roberto Cappai, et al.. (1996). 394 Characterisation of APP secretases in P. pastoris transfected with human full length APP695 cDNA. Neurobiology of Aging. 17(4). S98–S99. 3 indexed citations
12.
Pier, Gerald B., Dennis E. Desjardin, Martha Grout, et al.. (1994). Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infection and Immunity. 62(9). 3972–3979. 65 indexed citations
13.
14.
Stevens, Roy H., et al.. (1992). Blood spot screening and confirmatory tests for syphilis antibody. Journal of Clinical Microbiology. 30(9). 2353–2358. 17 indexed citations
15.
Fuller, Steve, et al.. (1989). Visuwell Reagin, a non-treponemal enzyme-linked immunosorbent assay for the serodiagnosis of syphilis. Journal of Clinical Microbiology. 27(10). 2300–2304. 9 indexed citations
16.
Fuller, Steve, et al.. (1988). Production of murine hybrid-hybridomas secreting bispecific monoclonal antibodies for use in urease-based immunoassays.. Clinical Chemistry. 34(9). 1693–1696. 17 indexed citations
17.
Fuller, Steve, Ming M. Wong, & John G.R. Hurrell. (1987). Immunochemical studies on the antigens of. Veterinary Immunology and Immunopathology. 17(1-4). 345–356. 4 indexed citations
18.
Chandler, Howard M., et al.. (1987). An accelerated enzyme immunoassay for human choriogonadotropin in urine, involving reflow of specimen through capillary tubes.. PubMed. 33(4). 498–501. 5 indexed citations
19.
Fuller, Steve, et al.. (1985). Affinity purification and refined structural characterization of terminal deoxynucleotidyltransferase. Biochemical Journal. 231(1). 105–113. 9 indexed citations
20.
Deibel, Martin R., Lela K. Riley, Mary Sue Colemán, et al.. (1983). Expression of terminal deoxynucleotidyl transferase in human thymus during ontogeny and development.. The Journal of Immunology. 131(1). 195–200. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gayathri Arakere Breakdown of academic impact, for papers by Jawad Sarwar Breakdown of academic impact, for papers by A. M. J. J. Verweij-Van Vught Breakdown of academic impact, for papers by Minako Araake Breakdown of academic impact, for papers by M. Campa Breakdown of academic impact, for papers by Jean Kirihara Breakdown of academic impact, for papers by C Cellesi Breakdown of academic impact, for papers by Thomas E. Grys Breakdown of academic impact, for papers by Imad Kansau Breakdown of academic impact, for papers by Ashley Keller
Rankless by CCL
2026